Management of acute stroke in patients taking novel oral anticoagulants
(2014) In International Journal of Stroke 9(5). p.627-632- Abstract
- Each year, 1 center dot 0-2 center dot 0% of individuals with atrial fibrillation and 0 center dot 1-0 center dot 2% of those with venous thromboembolism who are receiving one of the novel oral anticoagulants (dabigatran, rivaroxaban, or apixaban) can be expected to experience an acute ischemic stroke. Additionally, 0 center dot 2-0 center dot 5% of individuals with atrial fibrillation who are receiving one of the novel oral anticoagulants can be expected to experience an intracranial hemorrhage. This opinion piece addresses the current literature and offers practical approaches to the management of patients receiving novel oral anticoagulants who present with an ischemic or hemorrhagic stroke. Specifically, we discuss the role of... (More)
- Each year, 1 center dot 0-2 center dot 0% of individuals with atrial fibrillation and 0 center dot 1-0 center dot 2% of those with venous thromboembolism who are receiving one of the novel oral anticoagulants (dabigatran, rivaroxaban, or apixaban) can be expected to experience an acute ischemic stroke. Additionally, 0 center dot 2-0 center dot 5% of individuals with atrial fibrillation who are receiving one of the novel oral anticoagulants can be expected to experience an intracranial hemorrhage. This opinion piece addresses the current literature and offers practical approaches to the management of patients receiving novel oral anticoagulants who present with an ischemic or hemorrhagic stroke. Specifically, we discuss the role of thrombolysis in anticoagulated patients with acute ischemic stroke and factors to consider concerning restarting anticoagulation after acute ischemic and hemorrhagic stroke. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/4609430
- author
- Hankey, Graeme J. ; Norrving, Bo LU ; Hacke, Werner and Steiner, Thorsten
- organization
- publishing date
- 2014
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- acute stroke, anticoagulants, intracerebral hemorrhage, secondary, prevention, thrombolytic therapy
- in
- International Journal of Stroke
- volume
- 9
- issue
- 5
- pages
- 627 - 632
- publisher
- Wiley-Blackwell
- external identifiers
-
- wos:000337588200019
- scopus:84902084942
- pmid:24891030
- ISSN
- 1747-4949
- DOI
- 10.1111/ijs.12295
- language
- English
- LU publication?
- yes
- id
- 419ffa44-aef3-4d17-b6f1-cda6bc540531 (old id 4609430)
- date added to LUP
- 2016-04-01 11:12:39
- date last changed
- 2022-04-20 17:50:52
@article{419ffa44-aef3-4d17-b6f1-cda6bc540531,
abstract = {{Each year, 1 center dot 0-2 center dot 0% of individuals with atrial fibrillation and 0 center dot 1-0 center dot 2% of those with venous thromboembolism who are receiving one of the novel oral anticoagulants (dabigatran, rivaroxaban, or apixaban) can be expected to experience an acute ischemic stroke. Additionally, 0 center dot 2-0 center dot 5% of individuals with atrial fibrillation who are receiving one of the novel oral anticoagulants can be expected to experience an intracranial hemorrhage. This opinion piece addresses the current literature and offers practical approaches to the management of patients receiving novel oral anticoagulants who present with an ischemic or hemorrhagic stroke. Specifically, we discuss the role of thrombolysis in anticoagulated patients with acute ischemic stroke and factors to consider concerning restarting anticoagulation after acute ischemic and hemorrhagic stroke.}},
author = {{Hankey, Graeme J. and Norrving, Bo and Hacke, Werner and Steiner, Thorsten}},
issn = {{1747-4949}},
keywords = {{acute stroke; anticoagulants; intracerebral hemorrhage; secondary; prevention; thrombolytic therapy}},
language = {{eng}},
number = {{5}},
pages = {{627--632}},
publisher = {{Wiley-Blackwell}},
series = {{International Journal of Stroke}},
title = {{Management of acute stroke in patients taking novel oral anticoagulants}},
url = {{http://dx.doi.org/10.1111/ijs.12295}},
doi = {{10.1111/ijs.12295}},
volume = {{9}},
year = {{2014}},
}